New Concerns Arise Over Early Deaths in CAR-T Myeloma Trials with Carvykti and Abecma
Washington, D.C. – The Food and Drug Administration (FDA) has raised concerns about early deaths in clinical trials for CAR-T therapies used to treat multiple myeloma. Specifically, the FDA flagged the experimental treatments Carvykti from J&J and Legend, as well as Abecma from Bristol Myers Squibb. During the trials, patients receiving these CAR-T therapies experienced unexpected deaths, prompting the FDA to issue a warning. While CAR-T therapies have shown promising results in treating certain types …